BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook

Reuters

Jan 09

BRIEF-<a href="https://laohu8.com/S/PVLA">Palvella Therapeutics</a> Provides Corporate Update And 2026 Outlook

Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:

PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES
PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026
PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026
PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026
PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026

Source text: ID:nGNX2QwHlD

Further company coverage: PVLA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602375197"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602375197\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602375197?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602375197","market":"fut","top_or_hot":-1,"title":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> Provides Corporate Update And 2026 Outlook </title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES</p></li><li><p>PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX2QwHlD</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PVLA\">Palvella Therapeutics</a> Provides Corporate Update And 2026 Outlook </title></head><body><p><span>Jan 9 (Reuters)</span><span> - </span>Palvella <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>PVLA.O</span>:</p><ul><li><p>PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES</p></li><li><p>PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026</p></li><li><p>PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX2QwHlD</span></p><p>Further company coverage: <span>PVLA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA2JF0NP:1","article_id":"2602375197","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602375197","pubTimestamp":1767963328,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PVLA":"Palvella Therapeutics"},"translate_title":"简介-Palvella Therapeutics提供公司最新动态和2026年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PVLA":0.9},"content_text":"BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIESPALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026Source text: ID:nGNX2QwHlDFurther company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}